Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Study ID
- NCT03358134
- Phase
- PHASE3
- Status
- Completed
Conditions
- Spondylarthropathies
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Secukinumab — DRUGanti IL17 therapy (subcutaneous)
Study Details
The purpose of this study is to determine the mechanism of action on target tissue level of anti Interleukine-17 (anti-IL-17) an therapy in peripheral spondyloarthritis. Patients will be treated with anti-IL-17 therapy (secukinumab) for 12 weeks and with a 2 year extension period thereafter. At week 0 and 12 peripheral blood, synovial tissue and skin will be analysed with different techniques, including immunohistochemistry, RNA analysis and tissue culture to assess the effect of the therapy on inflammatory pathways.
Key Dates
- Start date
- Mar 31, 2014
- Status verified
- Nov 2017
- Primary completion
- Jul 31, 2017
- Completion
- Oct 31, 2017
Study Design
- Enrollment
- 20 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: SecukinumabAll patients will be treated with active treatment. (anti-IL17)
Primary Outcome Measure
Biological changes induced by therapy on target tissue (synovium) [ Time Frame: week 0 and week 12 ]